Satelite Symposia

Sunday, 17 February

12:00 – 13:15 Seehorn

Satellite Symposium Boehringer Ingelheim (a lunch bag will be offered)

Empagliflozin: From diabetes control to cardiovascular protection

Chairman :
T. F. Lüscher, London, Zurich

12:00 – 12:25

EMPA-REG® OUTCOME: Breakthrough in diabetes care

S. D. Anker, Berlin
12:25 – 12:50

EMPRISE® Program: Real-world evidences on Empagliflozin efficacy, safety and costs

A. Karasik, Ramat Gan
12:50 – 13:15

Panel discussion

18:00 – 19:15 Davos 2

Satellite Symposium Sanofi

ODYSSEY: Safe arrival of the flagship for PCSK9 inhibition

Chairs:
S. Windecker, Berne

F. Mach, Geneva


18:00 – 18:20

Are we all hyperlipidemic? Lessons from evolution

T. F. Lüscher, London
18:20 – 18:40

ODYSSEY OUTCOMES: What does a cardiologist need to know

P. G. Steg, Paris
18:40 – 19:00

Risk stratification in secondary prevention: Identification of the right patients for PCSK9 inhibition

B. Ference, Cambridge
19:00 – 19:15

Panel discussion